Boosting ADR Reporting: Assessing Knowledge, Attitude, and Practices Among UAE Hospital Pharmacists

By HEOR Staff Writer

August 2, 2023

A recent study aimed to evaluate the knowledge, attitudes, and practices (KAP) of hospital pharmacists in the UAE regarding Adverse Drug Reaction (ADR) reporting and the barriers to implementing a Pharmacovigilance (PV) system.

Although pharmacists generally display a positive attitude towards ADR reporting, the level of reporting remains low, which may be due to a lack of knowledge about PV and ADRs, including what, where, and when to report.

Interestingly, findings showed that gender does not affect awareness of PV and ADR reporting, but educational level and years of experience do. Hospital pharmacists with less than five years of experience lack the expertise of those with 10-14 years of experience in PV and ADR reporting.

Despite observing ADRs, only half of the participants reported them. This underreporting could be due to poor time management, lack of awareness of the reporting process, difficulties in accessing ADR reports, and poor patient-pharmacist communication.

They also found that the role and years of experience influence the likelihood of ADR reporting. Clinical pharmacists and inpatient pharmacists are more likely to engage in PV due to their direct patient care experience.

In terms of barriers, over half of the pharmacists cited a lack of knowledge about the reporting process. Fear of repercussions from management and legal culpability were also mentioned.

To improve ADR reporting, they recommend incentives for reporting, conducting workshops and ongoing education, providing legal protection, and ensuring easy online access to ADR forms.

Reference url

Recent Posts

New Federal Actions to Combat Misleading Prescription Drug Ads in 2025

By João L. Carapinha

September 11, 2025

Misleading prescription drug ads have become a pressing concern in the United States, prompting decisive federal action. What are the new measures targeting deceptive pharmaceutical advertising, and how will these changes affect public health and healthcare costs? In September 2025, a
Ending Unproven Fertility Treatments: NICE Calls for Evidence-Based Care in Clinics

By João L. Carapinha

September 10, 2025

Unproven fertility treatments—a term referring to add-on procedures without robust clinical evidence—have come under renewed scrutiny in the UK. Many prospective parents want to know: Why are unproven fertility treatments being discouraged, and what does this mean for fertility clinic choices...
Medicare ACO Outcomes: Balancing Surgical Benefits and Costs Under the TEAM Model

By João L. Carapinha

September 9, 2025

Medicare ACO outcomes are a major focus for clinicians, policymakers, and researchers seeking to understand how Accountable Care Organization (ACO) assignment influences patient results and healthcare costs after surgery. Are ACOs improving quality and saving money for Medicare patients undergoin...